Table 1. The Characteristics of RA patients and healthy controls.
| Characteristics | Patients (N = 402) | Controls (N = 969) | P-value (χ2 or t) | Patients (N = 563) | Controls (N = 1,542) | P-value (χ2 or t) |
|---|---|---|---|---|---|---|
| Discovery stage | Replication stage | |||||
| Age (years) | 50.46 ± 7.74 | 50.18 ± 8.07 | 0.551 (−0.597) | 52.37 ± 8.33 | 52.16 ± 8.25 | 0.604 (−0.519) |
| Gender (female/male) (%) | 315/87 (78.4%/21.6%) | 756/213 (78.0%/22.0%) | 0.890 (0.019) | 416/147 (73.9%/26.1%) | 1137/405 (73.7%/26.3%) | 0.943 (0.005) |
| Disease duration (months) | 48.37 ± 20.42 | NA | NA | 50.23 ± 24.38 | NA | NA |
| RF seropositivity [n (%)] | 343 (85.32%) | NA | NA | 468 (83.13%) | NA | NA |
| Anti-CCP positive [n (%)] | 312 (77.61%) | NA | NA | 441 (78.33%) | NA | NA |
| Anti-GPI positive [n (%)] | 249 (61.94%) | NA | NA | 352 (62.52%) | NA | NA |
| ESR (mm/h) | 41.27 ± 18.42 | NA | NA | 43.79 ± 18.58 | NA | NA |
| VAS | 44.19 ± 3.43 | NA | NA | 42.90 ± 3.07 | NA | NA |
| DAS28 score | 6.16 ± 0.60 | NA | NA | 5.94 ± 0.54 | NA | NA |
| Patients with erosions [n (%)] | 238 (59.20%) | NA | NA | 312 (55.42%) | NA | NA |
| Patients with extra-articular features [n (%)] | 52 (12.94%) | NA | NA | 55 (9.77%) | NA | NA |
Data were shown as mean ± SD, except gender. NA, not applicable; RA, rheumatoid arthritis; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide antibody; anti-GPI, anti-Glucose phosphate isomerase; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale; DAS28, 28-joints disease activity score.